Texas Permanent School Fund Corp Sells 213,755 Shares of Pfizer Inc. $PFE

Texas Permanent School Fund Corp lessened its holdings in Pfizer Inc. (NYSE:PFE) by 34.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 398,797 shares of the biopharmaceutical company’s stock after selling 213,755 shares during the quarter. Texas Permanent School Fund Corp’s holdings in Pfizer were worth $9,667,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. GKV Capital Management Co. Inc. bought a new position in Pfizer in the first quarter valued at approximately $27,000. Curio Wealth LLC lifted its stake in shares of Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,098 shares during the period. Bayforest Capital Ltd bought a new position in shares of Pfizer in the 1st quarter worth $28,000. Harbor Asset Planning Inc. acquired a new stake in shares of Pfizer during the second quarter worth $29,000. Finally, Howard Hughes Medical Institute bought a new stake in Pfizer in the second quarter valued at about $30,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE opened at $26.45 on Tuesday. The firm has a market cap of $150.37 billion, a P/E ratio of 15.38 and a beta of 0.46. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.69. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The firm’s 50 day moving average price is $25.12 and its two-hundred day moving average price is $24.80.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.5%. The ex-dividend date is Friday, January 23rd. Pfizer’s payout ratio is 100.00%.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Sanford C. Bernstein restated a “market perform” rating and set a $30.00 target price on shares of Pfizer in a report on Friday, October 31st. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Scotiabank began coverage on shares of Pfizer in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 target price for the company. BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. Finally, Bank of America lowered their price objective on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $28.22.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.